Business Wire

Conviva Announces Streaming Platform Expansion Solving Audience Measurement Challenges Globally

Share

Conviva, the continuous measurement platform for streaming media, today announces the availability of its technology and real-time data to enable end-to-end advertising audience measurement for its publisher customers and their ecosystem partners.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005928/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Conviva's streaming platform expansion delivers purpose-built technology and real-time data to enable end-to-end advertising audience measurement for publisher customers and their ecosystem partners. (Grapic: Business Wire)

Conviva’s global streaming audience measurement technology promises to deliver unique, innovative, and industry-changing solutions based on:

Session-level and census-level measurement

Antiquated third-party web technologies like beacons, logs, pixels or outdated and inaccurate panel methodologies are incapable of dealing with today’s complex device fragmentation. Conviva’s Stream Sensor™ provides continuous collection of every single session using standardized data collection and processing techniques for both session-level and census-level comprehensiveness. This provides a foundation of complete, comprehensive, uniform data that the entire ecosystem can rely on for accurate audience measurement, by eliminating inaccuracies within statistical inferences.

Future-proofed identity

Identity, a necessary pillar for accurate advertising audience measurement, is increasingly unstable due to privacy-regulations, third-party interference, and the rapid growth of anonymized ad-supported viewership. Conviva’s Stream ID™ provides consistent, persistent, accurate identity solutions using the best available first-party data possible, while still accommodating consumer choice and privacy regulations globally.

Ecosystem interoperability

In order to operate effectively in the complex world of audience measurement, content syndication, and cross-platform measurement, publishers must be able to activate their streaming data and audience with multiple ecosystem partners. Conviva’s platform expansion supplying Stream ID, and the Stream Sensor data it carries, are built using a common identity model that creates ecosystem interoperability, from both content partners and ecosystem activation destinations.

Publisher control

For the first time in the history of digital media, premium publishers are now in full control of their streaming data and audience, no longer relying on ‘currency tax’ vendors. This will help the premium publisher ecosystem compete effectively against the hegemony of walled gardens by giving advertisers the audience and context they need to address brand safety concerns.

Conviva certification

Conviva is fully committed to participating in the complete audit and accreditation processes including the Media Ratings Council (MRC) in the U.S. and other relevant industry auditing bodies globally, to certify new census-level standards that surpass any statistical inference accuracy certifications. This vital step ensures that data collection and reporting standards are upheld, to provide brands and agencies confidence in the accuracy of Conviva's audience measurement and reporting.

Conviva’s evolution is being led by the company’s recently-appointed President and CEO, Keith Zubchevich, a streaming industry veteran with more than a decade at Conviva. In his previous role as Chief Strategy Officer, Zubchevich worked closely with customers to understand their pain points and drive Conviva’s innovation to solve them, relationships that continue to inform his strategy as CEO.

“Today Conviva is already underfoot with premium publishers, collecting 3 trillion streaming events daily with insight into 500 million unique viewers globally,” comments Zubchevich. “The fact is Conviva has already solved for the incredibly complex challenge of standardized, census-level streaming measurement and is now working with our premium publishers and their ecosystem partners to introduce a new standard of audience measurement and quality to the global industry, to enable long-overdue innovation and change.”

About Conviva

Conviva is the census, continuous measurement and engagement platform for streaming media. Powered by our patented Stream Sensor™ and Stream ID™, our real-time platform enables marketers, advertisers, tech ops, engineering and customer care teams to acquire, engage, monetize and retain their audiences. Conviva is dedicated to supporting brands like CCTV, DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock the incredible opportunity in streaming media. Today our platform processes nearly 3 trillion streaming data events daily, supporting more than 500 million unique viewers watching 200 billion streams per year across 4 billion applications streaming on devices. Conviva ensures digital businesses of all sizes can stream better—every stream, every screen, every second. To learn more, visit www.conviva.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Paula Winkel
pr@conviva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye